Inventor

Vanitha Ramakrishnan

Inventor

Belmont, CA, US

Overview

19→

Patents

1998–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 19 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides35%

A61KPreparations for medical, dental or toiletry purposes30%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%

A01KAnimal husbandry2%

C12NMicroorganisms or enzymes2%

G01NInvestigating or analysing materials by determining their chemical or physical properties2%

PatentTitleYear

10,954,311Trispecific binding proteins and methods of use2021 9,708,412'Trispecific binding proteins and methods of use'2017 8,309,084'Chimeric and humanized antibodies to Î±5Î²1 integrin that modulate angiogenesis'2012 8,257,708'Antibodies against cancer antigen TMEFF2 and uses thereof'2012 8,017,116'Chimeric and humanized antibodies to Î±5Î²1 integrin that modulate angiogenesis'2011 7,897,148'Chimeric and humanized antibodies to Î±5Î²1 integrin that modulate angiogenesis'2011 7,879,987'Chimeric and humanized antibodies to Î±5Î²1 integrin that modulate angiogenesis'2011 7,824,678'Antibodies against cancer antigen TMEFF2 and uses thereof'2010 7,785,816'Antibodies against cancer antigen TMEFF2 and uses thereof'2010 7,776,585'Chimeric and humanized antibodies to Î±5Î²1 integrin that modulate angiogenesis'2010 7,674,883'Antibodies against cancer antigen TMEFF2 and uses thereof'2010 7,662,384'Use of anti-Î±5Î²1 antibodies to inhibit cancer cell proliferation'2010 7,399,469'Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer'2008 7,288,248'Antibodies against cancer antigen TMEFF2 and uses thereof'2007 7,285,268'Chimeric and humanized antibodies to Î±5Î²1 integrin that modulate angiogenesis'2007 7,276,589'Chimeric and humanized antibodies to Î±5Î²1 integrin that modulate angiogenesis'2007 7,060,271'Inhibitory immunoglobulin polypeptides to human PDGF beta receptor'2006 6,953,874'Transgenic animals having a modified glycoprotein V gene'2005 5,817,310'Inhibitory immunoglobulin polypeptides to human PDGF beta receptor'1998

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1998–2021Based in Belmont, CA, US· patent location history

2007–2008Patents assigned to PDL BIOPHARMA INC (4)· patent assignee history

2010–2011Patents assigned to FACET BIOTECH CORP (6)· patent assignee history

2011–2012Patents assigned to ABBOTT BIOTHERAPEUTICS CORP (4)· patent assignee history

2012Patents assigned to BHASKAR VINAY (2)· patent assignee history

2017–2021Patents assigned to HARPOON THERAPEUTICS INC (2)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
FACET BIOTECH CORP	6	2010–2011
ABBOTT BIOTHERAPEUTICS CORP	4	2011–2012
PDL BIOPHARMA INC	4	2007–2008
BHASKAR VINAY	2	2012
HARPOON THERAPEUTICS INC	2	2017–2021

Locations

Location	Patents	Span
Belmont, California, US	19	1998–2021